Literature DB >> 21383178

Protein farnesylation inhibitors cause donut-shaped cell nuclei attributable to a centrosome separation defect.

Valerie L R M Verstraeten1, Lana A Peckham, Michelle Olive, Brian C Capell, Francis S Collins, Elizabeth G Nabel, Stephen G Young, Loren G Fong, Jan Lammerding.   

Abstract

Despite the success of protein farnesyltransferase inhibitors (FTIs) in the treatment of certain malignancies, their mode of action is incompletely understood. Dissecting the molecular pathways affected by FTIs is important, particularly because this group of drugs is now being tested for the treatment of Hutchinson-Gilford progeria syndrome. In the current study, we show that FTI treatment causes a centrosome separation defect, leading to the formation of donut-shaped nuclei in nontransformed cell lines, tumor cell lines, and tissues of FTI-treated mice. Donut-shaped nuclei arise during chromatin decondensation in late mitosis; subsequently, cells with donut-shaped nuclei exhibit defects in karyokinesis, develop aneuploidy, and are often binucleated. Binucleated cells proliferate slowly. We identified lamin B1 and proteasome-mediated degradation of pericentrin as critical components in FTI-induced "donut formation" and binucleation. Reducing pericentrin expression or ectopic expression of nonfarnesylated lamin B1 was sufficient to elicit donut formation and binucleated cells, whereas blocking proteasomal degradation eliminated FTI-induced donut formation. Our studies have uncovered an important role of FTIs on centrosome separation and define pericentrin as a (indirect) target of FTIs affecting centrosome position and bipolar spindle formation, likely explaining some of the anticancer effects of these drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21383178      PMCID: PMC3064351          DOI: 10.1073/pnas.1019532108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen.

Authors:  T U Mayer; T M Kapoor; S J Haggarty; R W King; S L Schreiber; T J Mitchison
Journal:  Science       Date:  1999-10-29       Impact factor: 47.728

2.  The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner.

Authors:  Jun Zhou; Chantal Chanel Vos; Ada Gjyrezi; Minoru Yoshida; Fadlo R Khuri; Fuyuhiko Tamanoi; Paraskevi Giannakakou
Journal:  J Biol Chem       Date:  2009-02-18       Impact factor: 5.157

3.  Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities.

Authors:  James L Hougland; Katherine A Hicks; Heather L Hartman; Rebekah A Kelly; Terry J Watt; Carol A Fierke
Journal:  J Mol Biol       Date:  2009-10-28       Impact factor: 5.469

4.  The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.

Authors:  N C Crespo; J Ohkanda; T J Yen; A D Hamilton; S M Sebti
Journal:  J Biol Chem       Date:  2001-01-11       Impact factor: 5.157

5.  An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria.

Authors:  Brandon S J Davies; Richard H Barnes; Yiping Tu; Shuxun Ren; Douglas A Andres; H Peter Spielmann; Jan Lammerding; Yibin Wang; Stephen G Young; Loren G Fong
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

6.  Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules.

Authors:  H R Ashar; L James; K Gray; D Carr; S Black; L Armstrong; W R Bishop; P Kirschmeier
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

7.  Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers.

Authors:  Michael Lamson; Gale Phillips; Jason Shen; Peter Lukacsko; Lawrence Friedhoff; Robert M Niecestro
Journal:  Biopharm Drug Dispos       Date:  2002-05       Impact factor: 1.627

8.  Lamin B counteracts the kinesin Eg5 to restrain spindle pole separation during spindle assembly.

Authors:  Benjamin Goodman; Wilbur Channels; Minhua Qiu; Pablo Iglesias; Ge Yang; Yixian Zheng
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

9.  The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.

Authors:  N C Crespo; F Delarue; J Ohkanda; D Carrico; A D Hamilton; S M Sebti
Journal:  Cell Death Differ       Date:  2002-07       Impact factor: 15.828

10.  A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model.

Authors:  Brian C Capell; Michelle Olive; Michael R Erdos; Kan Cao; Dina A Faddah; Urraca L Tavarez; Karen N Conneely; Xuan Qu; Hong San; Santhi K Ganesh; Xiaoyan Chen; Hedwig Avallone; Frank D Kolodgie; Renu Virmani; Elizabeth G Nabel; Francis S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-06       Impact factor: 11.205

View more
  43 in total

1.  Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition.

Authors:  Valentine Comaills; Lilian Kabeche; Robert Morris; Rémi Buisson; Min Yu; Marissa Wells Madden; Joseph A LiCausi; Myriam Boukhali; Ken Tajima; Shiwei Pan; Nicola Aceto; Srinjoy Sil; Yu Zheng; Tilak Sundaresan; Toshifumi Yae; Nicole Vincent Jordan; David T Miyamoto; David T Ting; Sridhar Ramaswamy; Wilhelm Haas; Lee Zou; Daniel A Haber; Shyamala Maheswaran
Journal:  Cell Rep       Date:  2016-12-06       Impact factor: 9.423

2.  Loss of CENPF leads to developmental failure in mouse embryos.

Authors:  Cheng-Jie Zhou; Xing-Yue Wang; Zhe Han; Dong-Hui Wang; Yu-Zhen Ma; Cheng-Guang Liang
Journal:  Cell Cycle       Date:  2019-09-03       Impact factor: 4.534

3.  Centrosomal protein TRIM43 restricts herpesvirus infection by regulating nuclear lamina integrity.

Authors:  Florian Full; Michiel van Gent; Konstantin M J Sparrer; Cindy Chiang; Matthew A Zurenski; Myriam Scherer; Norbert H Brockmeyer; Lucie Heinzerling; Michael Stürzl; Klaus Korn; Thomas Stamminger; Armin Ensser; Michaela U Gack
Journal:  Nat Microbiol       Date:  2018-11-12       Impact factor: 17.745

4.  The Cep192-organized aurora A-Plk1 cascade is essential for centrosome cycle and bipolar spindle assembly.

Authors:  Vladimir Joukov; Johannes C Walter; Arcangela De Nicolo
Journal:  Mol Cell       Date:  2014-07-17       Impact factor: 17.970

5.  Nuclear deformability constitutes a rate-limiting step during cell migration in 3-D environments.

Authors:  Patricia M Davidson; Celine Denais; Maya C Bakshi; Jan Lammerding
Journal:  Cell Mol Bioeng       Date:  2014-09-01       Impact factor: 2.321

6.  Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins.

Authors:  Yuexia Wang; Cecilia Ostlund; Jason C Choi; Theresa C Swayne; Gregg G Gundersen; Howard J Worman
Journal:  Nucleus       Date:  2012-08-16       Impact factor: 4.197

7.  Reversal of laminopathies: the curious case of SUN1.

Authors:  Ya-Hui Chi; Chia-Yen Chen; Kuan-Teh Jeang
Journal:  Nucleus       Date:  2012-08-16       Impact factor: 4.197

8.  Non-farnesylated B-type lamin can tether chromatin inside the nucleus and its chromatin interaction requires the Ig-fold region.

Authors:  Ryo Uchino; Shin Sugiyama; Motoi Katagiri; Yoshiro Chuman; Kazuhiro Furukawa
Journal:  Chromosoma       Date:  2016-02-19       Impact factor: 4.316

9.  Disruption of lamin B1 and lamin B2 processing and localization by farnesyltransferase inhibitors.

Authors:  Stephen A Adam; Veronika Butin-Israeli; Megan M Cleland; Takeshi Shimi; Robert D Goldman
Journal:  Nucleus       Date:  2013-03-01       Impact factor: 4.197

Review 10.  The nuclear envelope environment and its cancer connections.

Authors:  Kin-Hoe Chow; Rachel E Factor; Katharine S Ullman
Journal:  Nat Rev Cancer       Date:  2012-02-16       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.